Abstract
ABSTRACT
Fibroblast activation protein (FAP) is a promising pan‐tumor target for theranostics, but current FAP‐targeted radioligands are limited by insufficient tumor retention and suboptimal therapeutic doses. To address these challenges, we developed a novel LARM platform and synthesized the FAPI dimer TH2103‐100. The radiochemical labeling efficiency of TH2103‐100 with
68
Ga was nearly 100% at room temperature (radio‐TLC), significantly surpassing that of FAPI‐04 (35.28% at room temperature and 79% at 95°C). The radiochemical purity of
68
Ga‐TH2103‐100 was >97%. In vitro experiments demonstrated that
68
Ga‐TH2103‐100 exhibited superior cellular uptake and enhanced binding affinity. In vivo experiments showed that, compared with FAPI‐04, tumor uptake was increased by 3.9‐fold with prolonged retention and no significant toxicity. In healthy volunteers, the effective dose was 3.69E‐02 mSv/MBq. Preliminary clinical studies showed that
68
Ga‐TH2103‐100 exhibited promising diagnostic performance compared to
18
F‐FDG. The LARM‐based
68
Ga‐TH2103‐100 enables efficient room‐temperature labeling and superior tumor targeting, providing complementary diagnostic value for cases with inconclusive
18
F‐FDG PET/CT findings and offering a new paradigm for next‐generation FAP‐targeted molecular imaging agents, while its potential as an adjunct to
18
F‐FDG warrants further validation.